Cerapedics, a privately-held orthobiologics company, today announced that the International Society for the Advancement of Spine Surgery (ISASS) issued a new bone grafting policy with recommendations on usage and payor coverage criterion that features i FACTOR™ Peptide Enhanced Bone Graft as one of only two drug-device combination products approved by the U.S. Food & Drug Administration (FDA) through the Premarket Approval (PMA) process and supported by level 1 clinical data

According to the U.S. Census Bureau, every year more than 1.6 million bonegrafting procedures are performed in the U.S. alone, and in each case, surgeons are faced with the critical decision of choosing an appropriate bone graft technology.

The finalists are in for the 10th annual PM360 Trailblazer Awards. PM360, a leading health-marketing industry trade magazine, will honor the pharmaceutical and medical device industries’ most influential innovators.

Cerapedics, a privately-held orthobiologics company, today announced that the first patients have been enrolled in an investigational device exemption (IDE) clinical trial evaluating the safety and efficacy of the next-generation P-15L Peptide Enhanced Bone Graft in transforaminal lumbar interbody fusion (TLIF) surgery.

Cerapedics, a privately-held orthobiologics company, today announced that the company completed a $22 million financing led by KCK Group, a family investment fund that focuses on innovative medical technologies that meet significant clinical needs.

Company recognized for i‑FACTOR™ Peptide Enhanced Bone Graft based on proprietary biomimetic small peptide technology

Cerapedics, a privately-held orthobiologics company, announced results from the IVANOS study evaluating i-FACTOR Peptide Enhanced Bone Graft in lumbar posterolateral spine surgery.

Cerapedics, a privately-held orthobiologics company, today announced the company received approval from the U.S. Food and Drug Administration (FDA) to initiate an investigational device exemption (IDE) clinical trial evaluating the safety and efficacy of P-15L Peptide Enhanced Bone Graft compared to autograft in transforaminal lumbar interbody fusion (TLIF) surgery for degenerative disk disease.

Cerapedics, a privately-held orthobiologics company, today announced that more than 150 leading U.S. hospitals have now adopted use of i-FACTOR™ Peptide Enhanced Bone Graft.

Cerapedics, a privately-held orthobiologics company, today announced the appointment of Doug Kohrs to the company’s board of directors and the appointment of Antony Koblish as board chair.

Oxford Finance LLC (“Oxford”), an industryleading specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced the closing of a $20 million senior secured term loan with Cerapedics Inc.

Cerapedics, a privately-held orthobiologics company, today announced the company has been awarded a group purchasing agreement with Premier Inc., a leading healthcare improvement company, for Breakthrough Technology: Bone Tissue Synthetic Implantable Products.

Cerapedics, a privately-held orthobiologics company, today announced it has received a Best New Technology Award for spine care as part of the 2016 Orthopedics This Week Spine Technology Awards.